24 Oct 2017,
  • HSI:
    28,305.88 -181.36 (-0.64%)
    HSCI:
    11,491.07 -67.28 (-0.58%)
    HKSPLC25:
    36,328.23 -221.48 (-0.61%)
    HKSPGEM:
    277.06 -0.55 (-0.20%)
  • HSCEI:
    11,491.07 -67.28 (-0.58%)
    HSCCI:
    4,394.17 -1.23 (-0.03%)
    HSFML25:
    9,962.34 -50.63 (-0.51%)
    H-FIN:
    18,492.56 -47.12 (-0.25%)
  • Hang Seng Index
  • 28,305.88

  • -181.36 (-0.64%)
HSCI 11,491.1 -67.3
HKSPLC25 36,328.2 -221.5
HKSPGEM 277.1 -0.6
HSCEI 11,491.1 -67.3
HSCCI 4,394.2 -1.2
HSFML25 9,962.3 -50.6
H-FIN 18,492.6 -47.1
Stay Connected With EQS TodayIR

Sinco Pharmaceuticals Holdings Limited (06833.HK)

Pharmaceuticals

INTRADAY CHART

more

FINANCIAL REPORTSmore

2017 (IR)
2016 (AR)
2016 (IR)

PRESENTATIONSmore

Sinco Pharmaceuticals Holdings Limited is the third largest provider of marketing, promotion and channel management, or MPCM, services in the PRC pharmaceutical industry with a market share of 6.4% based on revenue in 2014, according to the Frost & Sullivan Report. China’s MPCM services market, which had a market size of RMB14,959.8 million in 2014, is a subset of China’s pharmaceutical circulation market and accounted for approximately 1.0% of China’s pharmaceutical circulation market in 2014, according to the Frost & Sullivan Report. We are also China’s only MPCM services provider for plasma-based pharmaceuticals. China’s plasma-based pharmaceutical product market grew at a CAGR of 23.2% from 2010 to 2014, which is faster than the CAGR of both the overall China pharmaceutical market and China’s imported pharmaceutical market during the same period, according to the Frost & Sullivan Report. Driven by the unmet demand for plasma-based pharmaceuticals, favourable government initiatives, market development as well as technological improvements in the manufacturing process in China, the plasma-based pharmaceutical product market is expected to grow at a CAGR of 22.4% from 2015 to 2019 according to the Frost & Sullivan Report.
+ More Company Profile
Memorandum and Articles of Association
 
Internal Control and Corporate Governance Committee
 
Audit Committee
 
Nomination Committee
 
Remuneration Committee
 
Procedures for Shareholders to Propose A Person for Election As A Director
 
List of Directors and Their Roles and Functions
 
Board Diversity Policy
 
Shareholders Communication Policy Adopted Pursuant to A Resolution of the Board of Directors on 1 February, 2016
 

UPCOMING EVENT

S M T W T F S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31        

COMPANY INFORMATION

Listed Date 10 Mar 2016

Address E5-1805, New Century Global Center, 1700 Tianfu Avenue North, Gaoxin District, Chengdu, China

Telephone (86) 28 62912988

Facsimile (86) 28 62912922

Email sinco-pharm@sinco-pharm.cn

No. of Click Rate

56090